Remove 2023 Remove Communication Remove Pharmaceutical Manufacturing
article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

This poses a significant challenge for pharmaceutical manufacturers, not least because of the technical challenges related to operations, supply chain and the environment. This article explores the potential impact of the proposal and considers how manufacturers can ensure the safety and reliability of their products.

article thumbnail

Addressing US FDA challenges in Indian sterile drug manufacturing – Part 3

Express Pharma

Several high-profile global incidents serve as stark reminders of these risks: Global pharma healthcare eye drop contamination (India, 2023) Eye drops manufactured in Chennai by Global Pharma Healthcare and distributed under the EzriCare and Delsam Pharma brands in the U.S. FDA oversight.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

In August 2023, the therapy received investigational new drug clearance from China’s National Medical Products Administration to start a Phase I cancer trial. We may still continue to send you service-related and other non-promotional communications. Sign up for our daily news round-up!

article thumbnail

Specialty Pharmacist Integration in Neurology Clinics: A Model for Enhanced Patient Care

Pharmacy Times

Designed to manage patients with complex, chronic neurological conditions such as multiple sclerosis (MS), epilepsy, migraine, and movement disorders, the model aims to enhance medication access, streamline communication, and improve clinical outcomes. 1 Evidence from recent studies supports the effectiveness of this approach.

article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value from 2023 to 2024, reaching a total deal value of $2.81bn, according to GlobalData’s Pharma Intelligence Center Deals Database. Credit: Kateryna Kon via Shutterstock.

article thumbnail

Uncertainty looms over FDA scheme to boost US manufacturing

Pharmaceutical Technology

Robert Barrie August 8, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook More than half of pharmaceuticals distributed in the US are manufactured overseas. The PreCheck programme, unveiled by the FDA on 7 August 2025, comprises a two-phase approach to facilitate new US drug manufacturing facilities.

article thumbnail

NSW government invests $13.39m in life-changing therapies

Pharmaceutical Technology

The latest funding boost supplements an earlier announcement made during the 2023-24 budget, which provided A$25m in recurrent funding dedicated to similar initiatives. We may still continue to send you service-related and other non-promotional communications. Sign up for our daily news round-up!